Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Pascale Tomasini

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Journal of Thoracic Oncology

English

Bevacizumab in the Treatment of Nonsquamous Non-Small Cell Lung Cancer: Clinical Trial Evidence and Experience

Therapeutic Advances in Respiratory Disease

English

Related publications

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology

Cancer Research

Oncology

2018

English

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient With Disseminated Intravascular Coagulation

Journal of Thoracic Oncology

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

English

Rapid Response of Brain Metastasis to Crizotinib in a Patient With KLC1-ALK Fusion and MET Gene Amplification Positive Non-Small Cell Lung Cancer: A Case Report

Cancer Biology and Medicine

Cancer Research

Oncology

2017

English

Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Siberian Journal of Oncology

Cancer Research

Oncology

2020

English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management

2020

English

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology

English

ALK -Positive Diffuse Large B-Cell Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology

English

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Pascale Tomasini

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Bevacizumab in the Treatment of Nonsquamous Non-Small Cell Lung Cancer: Clinical Trial Evidence and Experience

Related publications

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient With Disseminated Intravascular Coagulation

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Rapid Response of Brain Metastasis to Crizotinib in a Patient With KLC1-ALK Fusion and MET Gene Amplification Positive Non-Small Cell Lung Cancer: A Case Report

Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

ALK -Positive Diffuse Large B-Cell Lymphoma

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer